Downstream Processing Featured Articles

  1. Success Of Engineered Tissue Depends On Where It's Grown 8/14/2012

    Tissue implants made of cells grown on a sponge-like scaffold have been shown in clinical trials to help heal arteries scarred by atherosclerosis and other vascular diseases. However, it has been unclear why some implants work better than others. By Anne Trafton

  2. Oncobiologics, Inc. Announces A Collaboration Agreement With XOMA Corporation To Utilize XOMA's Fully Human Antibody Libraries For Their Discovery Platform 7/30/2012

    Oncobiologics, Inc. announced recently a collaboration agreement with XOMA Corporation to develop novel biotherapeutics based on engineering single-chain variable fragments (scFv) into a bi-specific antibody scaffold.

  3. Lonza And Sartorius Stedim Biotech Enter Collaboration, Supply And Distribution Agreement In The Field Of Cell Culture Media 12/19/2012

    Lonza recently announced together with Sartorius Stedim Biotech (SSB), a leading international pharmaceutical and biotech supplier, a long-term global collaboration, supply and distribution agreement in the field of cell culture media.

  4. Evotec Acquires Cell Culture Service GmbH 1/3/2013

    Evotec AG recently announced the acquisition of all shares in Cell Culture Service GmbH (CCS), a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and Pharmaceutical companies.

  5. Element Six And The University Of Warwick Announce Development Of New Boron-Doped Synthetic Diamond Electrode For Extreme Electroanalysis Sensing Applications 3/18/2013

    AT PITTCON 2013, Element Six, the world leader in synthetic diamond supermaterials and member of the De Beers Group of Companies, recently announced that it has engineered DIAFILM EA (Electroanalysis grade) in collaboration with The University of Warwick.

  6. First Patient Treated In Genelux Phase I Trial With GL-ONC1 At Memorial Sloan Kettering Cancer Center 2/6/2013

    Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based cancer therapies and companion diagnostics, today announced that researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York treated the first patient in a Phase I clinical trial of GL-ONC1 in people with malignant pleural effusion, a complication that occurs in about 30 percent of lung cancers.

  7. New Insights Into HIV Vaccine Protection Will Improve Drug Development 1/28/2013

    Four years ago, a potential HIV vaccine showed promise against the virus that causes AIDS, but it fell short of providing the broad protection necessary to stem the spread of disease.

  8. ATMI Acquires European Biotech Firm To Expand Portfolio Of Bioprocess Manufacturing And Single-Use Technology Products For The Life Sciences Industry 11/4/2010
    ATMI, Inc. (Nasdaq:ATMI), announced today it has acquired the Belgian biotechnology firm Artelis S.A., an innovator in the area of highly-efficient bioprocesses and technologies for cell culture research and manufacturing scale-up. The acquisition complements ATMI's leadership in ultrapure single-use films, bioreactors, and mixing systems for characterizing, developing, and manufacturing biopharmaceuticals and extends its global capabilities to a broad range of biopharmaceutical process expertise.
  9. Study Identifies Human Melanoma Stem Cells 8/23/2012

    Cancer stem cells are defined by three abilities: differentiation, self-renewal and their ability to seed a tumor. These stem cells resist chemotherapy and many researchers posit their role in relapse.

  10. 3M Launches Large-Scale, Single-Use, Multi-Round Depth Filtration System 6/14/2012

    3M expanded its portfolio of Encapsulated Zeta Plus™ single-use depth filtration products to include our Model# 16EZC Multi-Round Holder.